Introduction: Cases of Multisystem Inflammatory Syndrome in Children (MISC) potentially
associated with COVID19 began to be reported in April 2020. This syndrome has similar
manifestations to Kawasaki Syndrome and many children may present complete or incomplete
criteria for this syndrome, which occurs mostly in older pediatric patients, adolescents and
schoolchildren, who have markers of inflammation, of coagulopathy and of myocardial injury
elevated. It is a pathology that involves at least two organs or systems. The main ones being
cardiac, respiratory, renal, hematological, dermatological, gastrointestinal or neurological.
Objective: Analyze the occurrence of Multisystem Inflammatory Syndrome in Children
associated with COVID19 in children from the state of Pará from april 2020 to august 2021.
Method: This is a crosssectional descriptive epidemiological study in which information from
the secondary database of notifications of Multisystem Inflammatory Syndrome in Children
(MISC) of the Secretaria de Saúde Pública do Pará (SESPA) was used. Results: 40 cases
affected by MISC were analyzed in Pará. 31 (78%) were diagnosed with COVID19 through
laboratory criteria and 9 (22%) through epidemiological criteria. The age ranged from 3 months
to 13 years, with a median of 3.5 years. The majority of the population studied was between 0
and 2 years old (lactants), corresponding to 16 cases (40%). The majority occurred in the male
sex, corresponding to 26 cases (65%). The municipalities with the highest number of confirmed
cases were Belém with 20 cases (50%); Barcarena with 3 cases (7.5%) and Castanhal also with
3 cases (7.5%). The diagnostic criteria for MISC associated with COVID19 that appeared the
most were fever greater than 38°C for 3 days or more, present in 40 cases (100%); elevation of
inflammatory markers in 39 cases (97.5%); evidence of COVID19 or history of close contact
with a confirmed case of COVID19 in 39 cases (97.5%). The most frequent symptoms were
diarrhea (62.5%); cough (47.5%); nausea and vomiting (45%) and abdominal pain (45%). As
for laboratory alterations, inflammatory markers were the most altered. There was a need for
admission to the Intensive Care Unit in 52% of cases. About the treatment performed in patients
in an ICU bed, the most used drug classes were corticosteroids in 76.19% and anticoagulants
in 57.14%. There were 5 deaths among the patients who needed ICU support. Of these, 4 had
comorbidities. Conclusion: Although most children and adolescents do not progress seriously
during COVID19, it was found that after infection by the virus, these patients can evolve with
an exacerbated immune system response, resulting in a multisystem inflammatory syndrome.
This study points to important results for the planning of health actions for the management of
MISC, through the provision of information about whether are the patients who evolved with
MISC¸ presence of previous comorbidities, treatment they performed, in addition to their
outcomes of the condition.
|
